PE20150706A1 - 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos - Google Patents
4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenosInfo
- Publication number
- PE20150706A1 PE20150706A1 PE2015000102A PE2015000102A PE20150706A1 PE 20150706 A1 PE20150706 A1 PE 20150706A1 PE 2015000102 A PE2015000102 A PE 2015000102A PE 2015000102 A PE2015000102 A PE 2015000102A PE 20150706 A1 PE20150706 A1 PE 20150706A1
- Authority
- PE
- Peru
- Prior art keywords
- pentaaza
- cyclopenta
- methyl
- naphthalenes
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A DERIVADOS DE 4-METIL-2,3,5,9,9b-PENTAAZA-CICLOPENTA[a]NAFTALENO DE FORMULA (I) DONDE A, R1, R2, R3, R4, R5 Y R6 SON COMO SE DEFINEN EN LA DESCRIPCION. TAMBIEN SE REFIERE A UN PROCESO PARA LA ELABORACION DE LOS COMPUESTOS Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA FOSFODIESTERASA 2 Y 10 SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL TAL COMO DEMENCIA, ESQUIZOFRENIA, EPILEPSIA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12178713 | 2012-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20150706A1 true PE20150706A1 (es) | 2015-06-03 |
Family
ID=48906250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015000102A PE20150706A1 (es) | 2012-07-31 | 2013-07-29 | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos |
Country Status (28)
Country | Link |
---|---|
US (2) | US20140045856A1 (es) |
EP (1) | EP2882749B1 (es) |
JP (1) | JP6356671B2 (es) |
KR (1) | KR20150037950A (es) |
CN (1) | CN104428302B (es) |
AP (1) | AP2015008202A0 (es) |
AR (1) | AR091939A1 (es) |
AU (1) | AU2013298621B2 (es) |
BR (1) | BR112015002118A2 (es) |
CA (1) | CA2880447A1 (es) |
CL (1) | CL2015000096A1 (es) |
CO (1) | CO7310531A2 (es) |
EA (1) | EA028958B1 (es) |
EC (1) | ECSP15006871A (es) |
GE (1) | GEP201706707B (es) |
HK (1) | HK1208440A1 (es) |
IL (1) | IL236494A0 (es) |
MA (1) | MA37798B1 (es) |
MX (1) | MX2015000965A (es) |
NZ (1) | NZ703797A (es) |
PE (1) | PE20150706A1 (es) |
PH (1) | PH12015500211A1 (es) |
SG (1) | SG11201500772VA (es) |
TN (1) | TN2015000022A1 (es) |
TW (1) | TW201418255A (es) |
UA (1) | UA115561C2 (es) |
UY (1) | UY34955A (es) |
WO (1) | WO2014019979A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
EP2763989A1 (en) * | 2011-09-09 | 2014-08-13 | H. Lundbeck A/S | Pyridine compounds and uses thereof |
US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
EP3285581B1 (en) | 2015-03-26 | 2021-08-11 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
WO2016179059A1 (en) | 2015-05-05 | 2016-11-10 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as pde2 inhibitors |
WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
US10618898B2 (en) * | 2015-05-20 | 2020-04-14 | Guangdong Raynovent Biotech Co., Ltd. | Hydroxyl purine compounds and use thereof |
WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
WO2016192083A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
EP3313852B1 (en) | 2015-06-25 | 2021-01-20 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors |
WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
EP3156405A1 (en) * | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
EP3442538A4 (en) * | 2016-04-04 | 2019-11-20 | Sinopia Biosciences, Inc. | TREATMENT OF EXTRAPYRAMIDAL SYNDROME WITH TRAPIDILE |
AR112457A1 (es) * | 2017-08-02 | 2019-10-30 | Lilly Co Eli | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona |
JP2021504466A (ja) | 2017-11-23 | 2021-02-15 | オスロ ウニヴェルシティ ホスピタル ホーエフ | 頻脈の治療 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000319277A (ja) * | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
JP2000319278A (ja) * | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
DE10108752A1 (de) | 2001-02-23 | 2002-09-05 | Bayer Ag | Neue Substituierte Imidazotriazinone |
CA2520251A1 (en) | 2003-03-27 | 2004-10-07 | Pfizer Products Inc. | Substituted 4-amino[1,2,4]triazolo[4,3-a]quinoxalines |
WO2005041957A1 (en) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
UA83091C2 (en) | 2003-12-16 | 2008-06-10 | Пфайзер Продактс Инк. | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
FR2865331A1 (fr) | 2004-01-21 | 2005-07-22 | France Telecom | Procede de connexion d'un reseau domestique a un serveur cops distant et dispositif associe |
FR2870539B1 (fr) | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
ATE471324T1 (de) | 2004-09-02 | 2010-07-15 | Nycomed Gmbh | Triazolophthalazine |
AU2006204451C1 (en) | 2005-01-05 | 2012-05-24 | Takeda Gmbh | Triazolophthalazines as PDE2-inhibitors |
ES2397080T3 (es) | 2005-01-05 | 2013-03-04 | Nycomed Gmbh | Triazoloftalazinas como agentes inhibidores de la PDE2 |
BRPI0502411A (pt) | 2005-03-31 | 2006-11-28 | Univ Minas Gerais | processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados |
EP1978966A4 (en) | 2006-01-23 | 2010-11-10 | Amira Pharmaceuticals Inc | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE |
WO2007121319A2 (en) | 2006-04-14 | 2007-10-25 | University Of California | Compostions and methods for determining and predicting treatment responses for depression and anxiety |
TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
DE102006048693A1 (de) | 2006-10-14 | 2008-04-17 | Bayer Healthcare Ag | Inhibition der PDE2A |
ES2566774T3 (es) * | 2006-12-13 | 2016-04-15 | Aska Pharmaceutical Co., Ltd. | Derivado de quinoxalina |
US20090143361A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物 |
UY32111A (es) | 2008-09-10 | 2010-04-30 | Alcon Res Ltd | Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad |
US8415386B2 (en) | 2008-10-08 | 2013-04-09 | Bristol-Myers Squibb Company | Azolopyrrolone melanin concentrating hormone receptor-1 antagonists |
WO2010054253A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
EP2406250B1 (en) * | 2009-03-11 | 2015-08-12 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
EP2266985A1 (en) * | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Tricyclic Pyrimidine Derivatives as Wnt antagonists |
CN107141309A (zh) | 2011-01-11 | 2017-09-08 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
US10604523B2 (en) | 2011-06-27 | 2020-03-31 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
EP2763989A1 (en) | 2011-09-09 | 2014-08-13 | H. Lundbeck A/S | Pyridine compounds and uses thereof |
WO2013034758A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Substituted triazolopyrazines and uses thereof |
AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
RU2657540C2 (ru) | 2012-06-26 | 2018-06-14 | Янссен Фармацевтика Нв | Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств |
US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
-
2013
- 2013-07-18 US US13/945,008 patent/US20140045856A1/en not_active Abandoned
- 2013-07-26 US US13/951,531 patent/US9085584B2/en active Active
- 2013-07-29 GE GEAP201313748A patent/GEP201706707B/en unknown
- 2013-07-29 JP JP2015524750A patent/JP6356671B2/ja active Active
- 2013-07-29 NZ NZ703797A patent/NZ703797A/en not_active IP Right Cessation
- 2013-07-29 KR KR20157002607A patent/KR20150037950A/ko not_active Application Discontinuation
- 2013-07-29 AU AU2013298621A patent/AU2013298621B2/en not_active Ceased
- 2013-07-29 MX MX2015000965A patent/MX2015000965A/es unknown
- 2013-07-29 SG SG11201500772VA patent/SG11201500772VA/en unknown
- 2013-07-29 AP AP2015008202A patent/AP2015008202A0/xx unknown
- 2013-07-29 EP EP13742632.6A patent/EP2882749B1/en active Active
- 2013-07-29 CA CA2880447A patent/CA2880447A1/en not_active Abandoned
- 2013-07-29 BR BR112015002118A patent/BR112015002118A2/pt not_active IP Right Cessation
- 2013-07-29 EA EA201500182A patent/EA028958B1/ru not_active IP Right Cessation
- 2013-07-29 MA MA37798A patent/MA37798B1/fr unknown
- 2013-07-29 WO PCT/EP2013/065894 patent/WO2014019979A1/en active Application Filing
- 2013-07-29 UA UAA201501673A patent/UA115561C2/uk unknown
- 2013-07-29 PE PE2015000102A patent/PE20150706A1/es not_active Application Discontinuation
- 2013-07-29 CN CN201380037349.6A patent/CN104428302B/zh not_active Expired - Fee Related
- 2013-07-30 TW TW102127314A patent/TW201418255A/zh unknown
- 2013-07-30 AR ARP130102708A patent/AR091939A1/es unknown
- 2013-07-31 UY UY0001034955A patent/UY34955A/es unknown
-
2014
- 2014-12-28 IL IL236494A patent/IL236494A0/en unknown
-
2015
- 2015-01-14 CL CL2015000096A patent/CL2015000096A1/es unknown
- 2015-01-16 TN TNP2015000022A patent/TN2015000022A1/fr unknown
- 2015-01-29 CO CO15018184A patent/CO7310531A2/es unknown
- 2015-01-30 PH PH12015500211A patent/PH12015500211A1/en unknown
- 2015-02-25 EC ECIEPI20156871A patent/ECSP15006871A/es unknown
- 2015-09-11 HK HK15108887.2A patent/HK1208440A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20150706A1 (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
CR20170237A (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
PE20150669A1 (es) | Derivados de benzamida para la inhibicion de la actividad de abl1, abl2 y bcr-abl1 | |
ECSP13012892A (es) | IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS | |
UY34917A (es) | Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación | |
GT201400131A (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
ECSP11011258A (es) | Pirimidinas fusionadas | |
UY33557A (es) | Inhibidores de oxadiazol de la produccion de leucotrieno | |
CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
UY36226A (es) | Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble | |
CO7131360A2 (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
PE20150966A1 (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina | |
UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
PH12017500595A1 (en) | Aldosterone synthase inhibitors | |
CO2017000011A2 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
UY36228A (es) | Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen | |
CR20140325A (es) | Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2- | |
ECSP13012548A (es) | Inhibidores de oxadiazol de la producción de leucotrienos. | |
UY34281A (es) | "1,4-diazabiciclo[3.2.2]nonanos como ligandos de receptores nicotínicos neuronales de acetilcolina | |
ECSP099644A (es) | Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico | |
CO2017003225A2 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos | |
GB2527958A (en) | Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents | |
ECSP14011506A (es) | Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |